NASDAQ:KRYS Krystal Biotech (KRYS) Stock Forecast, Price & News $115.68 +0.33 (+0.29%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$114.34▼$116.9050-Day Range$108.51▼$130.2252-Week Range$61.11▼$132.68Volume202,600 shsAverage Volume260,531 shsMarket Capitalization$3.24 billionP/E RatioN/ADividend YieldN/APrice Target$137.57 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Krystal Biotech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside18.9% Upside$137.57 Price TargetShort InterestBearish5.68% of Shares Sold ShortDividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.49Based on 8 Articles This WeekInsider TradingSelling Shares$3.18 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.97) to ($1.12) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.02 out of 5 starsMedical Sector598th out of 976 stocksBiotechnology Industry11th out of 18 stocks 2.5 Analyst's Opinion Consensus RatingKrystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $137.57, Krystal Biotech has a forecasted upside of 18.9% from its current price of $115.68.Amount of Analyst CoverageKrystal Biotech has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.68% of the outstanding shares of Krystal Biotech have been sold short.Short Interest Ratio / Days to CoverKrystal Biotech has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Krystal Biotech has recently increased by 6.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKrystal Biotech does not currently pay a dividend.Dividend GrowthKrystal Biotech does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKrystal Biotech has received a 73.65% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for physical health", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Krystal Biotech is -0.87. Previous Next 2.5 News and Social Media Coverage News SentimentKrystal Biotech has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Krystal Biotech this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for KRYS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows1 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Krystal Biotech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,180,750.00 in company stock.Percentage Held by Insiders17.00% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.30% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Krystal Biotech are expected to grow in the coming year, from ($4.97) to ($1.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Krystal Biotech is -21.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Krystal Biotech is -21.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKrystal Biotech has a P/B Ratio of 5.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Krystal Biotech (NASDAQ:KRYS) StockKrystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Read More KRYS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KRYS Stock News HeadlinesSeptember 25, 2023 | finance.yahoo.comKrystal Biotech, Inc. (NASDAQ:KRYS): Are Analysts Optimistic?September 24, 2023 | americanbankingnews.comKrystal Biotech (NASDAQ:KRYS) Stock Price Down 2.3%September 28, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 22, 2023 | msn.comFDA clears Krystal Biotech’s IND for Type 1 AATD treatment KB408September 22, 2023 | msn.comKrystal Biotech: FDA Approval Of Vyjuvek And Further Pipeline EnhancementSeptember 21, 2023 | seekingalpha.comKrystal Biotech wins FDA nod to run trial for gene therapySeptember 21, 2023 | markets.businessinsider.comKrystal Biotech Announces FDA Clearance Of IND For KB408September 15, 2023 | msn.comHave Million-Dollar Gene Therapies Finally Reached An Inflection Point?September 28, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...September 13, 2023 | msn.comKrystal Biotech CEO sells shares worth $6.3MSeptember 13, 2023 | finance.yahoo.comInsider Sell: Suma Krishnan Sells 50,000 Shares of Krystal Biotech Inc (KRYS)September 7, 2023 | msn.comBerenberg starts Krystal Biotech at buy, cites upcoming drug launchSeptember 7, 2023 | msn.comBerenberg Initiates Coverage of Krystal Biotech (KRYS) with Buy RecommendationSeptember 7, 2023 | markets.businessinsider.com5 Analysts Have This to Say About Krystal BiotechSeptember 7, 2023 | finance.yahoo.comKrystal Biotech to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceSeptember 5, 2023 | msn.comKrystal Biotech gets FDA orphan drug designation for AATD drug candidateSeptember 5, 2023 | markets.businessinsider.comKrystal Biotech: FDA Grants Orphan Drug Designation For KB408September 5, 2023 | finance.yahoo.comKrystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin DeficiencyAugust 31, 2023 | msn.comKrystal Biotech (KRYS) Price Target Increased by 8.11% to 151.54August 22, 2023 | finance.yahoo.comKrystal (KRYS) Up 5% on Sale of FDA's Priority Review VoucherAugust 21, 2023 | markets.businessinsider.comKrystal Biotech Completes Sale Of Rare Pediatric Disease Priority Review VoucherAugust 21, 2023 | msn.comKrystal Biotech Sells Rare Pediatric Disease Priority Review Voucher For $100MAugust 21, 2023 | finance.yahoo.comKrystal Biotech sells priority review voucher for $100MAugust 21, 2023 | finance.yahoo.comKrystal Biotech Announces Sale of Priority Review Voucher for $100 MillionAugust 9, 2023 | msn.comChardan Capital Maintains Krystal Biotech (KRYS) Buy RecommendationAugust 8, 2023 | markets.businessinsider.comAnalyst Ratings for Krystal BiotechAugust 8, 2023 | marketwatch.comKrystal Biotech Shares Tumble 10% on Wider 2Q LossSee More Headlines Receive KRYS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address KRYS Company Calendar Last Earnings8/07/2023Today9/27/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KRYS CUSIPN/A CIK1711279 Webwww.krystalbio.com Phone(412) 586-5830FaxN/AEmployees210Year Founded2017Price Target and Rating Average Stock Price Forecast$137.57 High Stock Price Forecast$154.00 Low Stock Price Forecast$118.00 Forecasted Upside/Downside+19.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($5.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-25.46% Return on Assets-23.89% Debt Debt-to-Equity RatioN/A Current Ratio20.25 Quick Ratio20.25 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$20.28 per share Price / Book5.68Miscellaneous Outstanding Shares27,990,000Free Float23,235,000Market Cap$3.22 billion OptionableNot Optionable Beta0.83 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Krish S. Krishnan M.B.A. (Age 58)M.S., Founder, Chairman, Pres & CEO Comp: $1.07MMs. Suma M. Krishnan (Age 58)Founder, COO, Pres of R&D and Director Comp: $789.92kMs. Kathryn A. Romano (Age 41)Exec. VP & Chief Accounting Officer Comp: $528.87kMs. Meg DodgeVP of Investor Relations & Corp. CommunicationsMr. John KarakkalVP of North American Sales & MarketingMr. Josh SuskinDirector of HR & OperationsDr. Hubert C. Chen M.D. (Age 54)Sr. VP of Clinical Devel. Mr. Laurent GouxSr. VP & GM of EuropeMr. Ram KamineniSr. VP of CMC & Technical OperationsMr. David ChienSr. VP of Clinical Devel.More ExecutivesKey CompetitorsRevolution MedicinesNASDAQ:RVMDDenali TherapeuticsNASDAQ:DNLIGinkgo BioworksNYSE:DNACRISPR TherapeuticsNASDAQ:CRSPImmunocoreNASDAQ:IMCRView All CompetitorsInsiders & InstitutionsSuma KrishnanSold 25,000 sharesTotal: $3.18 M ($127.23/share)Wolverine Trading LLCBought 3,000 shares on 8/23/2023Ownership: 0.000%California State Teachers Retirement SystemBought 439 shares on 8/21/2023Ownership: 0.086%Osaic Holdings Inc.Bought 261 shares on 8/21/2023Ownership: 0.001%Legato Capital Management LLCBought 1,795 shares on 8/18/2023Ownership: 0.045%View All Insider TransactionsView All Institutional Transactions KRYS Stock - Frequently Asked Questions Should I buy or sell Krystal Biotech stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRYS shares. View KRYS analyst ratings or view top-rated stocks. What is Krystal Biotech's stock price forecast for 2023? 7 analysts have issued 12 month target prices for Krystal Biotech's shares. Their KRYS share price forecasts range from $118.00 to $154.00. On average, they predict the company's stock price to reach $137.57 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price. View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts. How have KRYS shares performed in 2023? Krystal Biotech's stock was trading at $79.22 at the start of the year. Since then, KRYS stock has increased by 45.3% and is now trading at $115.11. View the best growth stocks for 2023 here. Are investors shorting Krystal Biotech? Krystal Biotech saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,590,000 shares, an increase of 6.0% from the August 31st total of 1,500,000 shares. Based on an average trading volume of 268,500 shares, the days-to-cover ratio is currently 5.9 days. View Krystal Biotech's Short Interest. When is Krystal Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our KRYS earnings forecast. How were Krystal Biotech's earnings last quarter? Krystal Biotech, Inc. (NASDAQ:KRYS) posted its earnings results on Monday, August, 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.27) by $0.02. What ETFs hold Krystal Biotech's stock? ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Jacob Forward ETF (JFWD), Franklin Genomic Advancements ETF (HELX), ALPS Medical Breakthroughs ETF (SBIO), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Principal Healthcare Innovators ETF (BTEC).IQ Chaikin U.S. Small Cap ETF (CSML). What other stocks do shareholders of Krystal Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA). When did Krystal Biotech IPO? (KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO. What is Krystal Biotech's stock symbol? Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS." Who are Krystal Biotech's major shareholders? Krystal Biotech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.84%), State Street Corp (3.23%), Point72 Asset Management L.P. (2.00%), Dimensional Fund Advisors LP (1.74%), Credit Suisse AG (1.67%) and Geode Capital Management LLC (1.59%). Insiders that own company stock include Andrew C Orth, Daniel Janney, Dino A Rossi, Kathryn Romano, Krish S Krishnan and Suma Krishnan. View institutional ownership trends. How do I buy shares of Krystal Biotech? Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Krystal Biotech's stock price today? One share of KRYS stock can currently be purchased for approximately $115.11. How much money does Krystal Biotech make? Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $3.22 billion. The company earns $-139,980,000.00 in net income (profit) each year or ($5.43) on an earnings per share basis. How many employees does Krystal Biotech have? The company employs 210 workers across the globe. How can I contact Krystal Biotech? Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com. This page (NASDAQ:KRYS) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Krystal Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.